A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes

Registry ID

EUCTR2005-000473-22

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2005-10-11

Last update

2026-08-16

Conditions

• Type II Diabetes

Summary

To confirm the efficacy of LAF237 in patients with type 2 diabetes by testing the hypothesis that the hemoglobin A1c (HbA1c) reduction with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) is superior to that with placebo after 24 weeks of treatment.

Locations

• , , Slovakia

Related clinical trials

• The GRoceries Aimed at Increasing Nutrition Study
• Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
• Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients
• Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
• Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.

View on source registry